EU Backs Nycomed’s Daxas In Deadly Lung Disease; Drug Approval Could Spur Nycomed IPO

ZURICH July 6 (Reuters) - Nycomed's [NYCMD.UL] lung drug Daxas has won European Union backing to treat patients with chronic obstructive pulmonary disease, bringing to market the first new type of treatment for the disease in over a decade.